Glioblastoma is one of the most challenging cancers to treat due to its aggressive nature and resistance to standard therapies. In recent years, however, the field of glioblastoma immunotherapy has made significant strides, introducing innovative approaches like oncolytic viruses and brain cancer vaccines. These emerging treatments aim to engage the immune system in the fight against glioblastoma, offering new avenues for improving patient outcomes and extending survival rates.

The Current State of Glioblastoma Treatment

  With a median survival rate of only 12-15 months, glioblastoma patients face difficult odds. Traditional treatments often manage to slow tumor growth temporarily, but recurrence is common. This grim reality has motivated researchers to explore innovative therapies that leverage the body’s immune system, including oncolytic viruses and personalized vaccines.

(more…)